[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
May 1971


Author Affiliations

8625 S Cicero Ave Chicago

Arch Dermatol. 1971;103(5):560-561. doi:10.1001/archderm.1971.04000170094021

To the Editor.—  The immunologic approach to treatment of cancer and precancerous lesions is relatively new. It consists of enhancing the cellular immune mechanisms of the host in order to obtain rejection of the neoplasm. In recent years nonspecific agents have been used to stimulate the host's immune system. BCG vaccine has been used with limited success in acute leukemia1 and in malignant melanoma (Medical Tribune 1, 1970). Ratner and associates have used 2-4-dinitrochlorobenzene in mycosis fungoides with some success,2 although recurrence of lesions or development of new ones was almost always seen within months.3 In a more recent communication4 Van Scott and Winters reported complete remissions of from two to nine months in 11 of 14 patients with plaque stage of mycosis fungoides and in 3 of 4 patients with generalized erythema who had been treated with mechlorethamine hydrochloride (nitrogen mustard) topically. The best results

First Page Preview View Large
First page PDF preview
First page PDF preview